Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose

Overview

Journal Prev Chronic Dis

Specialty Public Health

Date 2022 Jul 14

PMID 35834737

Authors

Elizabeth Skoy

Oliver Frenzel

Heidi Eukel

Emily Lothspeich

Jayme Steig

Mark Strand

Amy Werremeyer

Affiliations

Soon will be listed here.

Abstract

Introduction: Community pharmacies nationwide have adopted new strategies to combat the opioid epidemic. One strategy to prevent opioid misuse and accidental overdose is patient screening to identify those at risk. The purpose of our study was to determine whether such screening in community pharmacies led pharmacy personnel to intervene with patients at risk and to describe the proportion of patients they identified as at risk.

Methods: We implemented the Opioid and Naloxone Education (ONE) program in North Dakota to give community pharmacies and pharmacists training and tools to provide preventive screening for opioid misuse and accidental overdose before dispensing a prescribed opioid. Data were collected and analyzed from September 15, 2018, through May 15, 2021, to evaluate overall patient risk characteristics for opioid misuse and accidental overdose.

Results: Of 8,217 patients screened, 3.9% were identified as at high risk for opioid misuse, and 18.3% at risk for accidental overdose. Nearly 1 of 3 screenings (31.7%) indicated opioid medication use in the past 60 days. Pharmacists delivered 1 or more risk-factor-dependent interventions to 41.1% of patients in the study. Following screening, naloxone dispensing in pharmacies increased to 6 times the national average.

Conclusion: Pharmacy-based patient screening for risk of opioid misuse and accidental overdose led to risk-dependent interventions targeted to individual patients. The tools and risk-dependent interventions applied in the ONE program increased patient awareness of opioid risks and ways to reduce risk. Future studies should examine long-term outcomes, including reduction in overdose, treatment of opioid use disorder, and reduced opioid-related acute care.

Citing Articles

Project Lifeline-II: Feasibility of Implementing Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Allegheny County, Pennsylvania.

Cloutier R, Dowd W, Aldridge A, Walsh C, Messman B, Northcott J Public Health Rep. 2024; :333549241277416.

PMID: 39342449 PMC: 11556627. DOI: 10.1177/00333549241277416.

Systematic literature review of the impact of psychiatric pharmacists.

Ho J, Roberts J, Payne G, Holzum D, Wilkoff H, Tran T Ment Health Clin. 2024; 14(1):33-67.

PMID: 38312443 PMC: 10836561. DOI: 10.9740/mhc.2024.02.033.

References

Cochran B, Flentje A, Heck N, Van Den Bos J, Perlman D, Torres J . Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend. 2014; 138:202-8. PMC: 4046908. DOI: 10.1016/j.drugalcdep.2014.02.701. View

Jones C, Lurie P, Compton W . Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013. Am J Public Health. 2016; 106(4):689-90. PMC: 4816011. DOI: 10.2105/AJPH.2016.303062. View

Chen Q, Larochelle M, Weaver D, Lietz A, Mueller P, Mercaldo S . Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. JAMA Netw Open. 2019; 2(2):e187621. PMC: 6415966. DOI: 10.1001/jamanetworkopen.2018.7621. View

Webster L, Webster R . Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005; 6(6):432-42. DOI: 10.1111/j.1526-4637.2005.00072.x. View

Bell N, Grad R, Dickinson J, Singh H, Moore A, Kasperavicius D . Better decision making in preventive health screening: Balancing benefits and harms. Can Fam Physician. 2017; 63(7):521-524. PMC: 5507224. View

Clark M, Hurley R, Adams M . Re-assessing the Validity of the Opioid Risk Tool in a Tertiary Academic Pain Management Center Population. Pain Med. 2018; 19(7):1382-1395. PMC: 7191882. DOI: 10.1093/pm/pnx332. View

McNeely J, Strauss S, Saitz R, Cleland C, Palamar J, Rotrosen J . A Brief Patient Self-administered Substance Use Screening Tool for Primary Care: Two-site Validation Study of the Substance Use Brief Screen (SUBS). Am J Med. 2015; 128(7):784.e9-19. PMC: 4475501. DOI: 10.1016/j.amjmed.2015.02.007. View

Green T, Donovan E, Klug B, Case P, Baird J, Burstein D . Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches. J Am Pharm Assoc (2003). 2020; 60(5):740-749. PMC: 10948012. DOI: 10.1016/j.japh.2020.03.005. View

Compton W, Jones C, Stein J, Wargo E . Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Social Adm Pharm. 2018; 15(8):910-916. PMC: 7373345. DOI: 10.1016/j.sapharm.2017.12.009. View

10.

Riley T, Alemagno S . Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients. Res Social Adm Pharm. 2019; 15(8):986-991. DOI: 10.1016/j.sapharm.2019.01.002. View

11.

Cochran G, Bacci J, Ylioja T, Hruschak V, Miller S, Seybert A . Prescription opioid use: Patient characteristics and misuse in community pharmacy. J Am Pharm Assoc (2003). 2016; 56(3):248-256.e6. PMC: 4886233. DOI: 10.1016/j.japh.2016.02.012. View

12.

Irvine M, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E . Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022; 7(3):e210-e218. PMC: 10937095. DOI: 10.1016/S2468-2667(21)00304-2. View

13.

Green T, Davis C, Xuan Z, Walley A, Bratberg J . Laws Mandating Coprescription of Naloxone and Their Impact on Naloxone Prescription in Five US States, 2014-2018. Am J Public Health. 2020; 110(6):881-887. PMC: 7204438. DOI: 10.2105/AJPH.2020.305620. View

14.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

15.

Thakur T, Frey M, Chewning B . Pharmacist Services in the Opioid Crisis: Current Practices and Scope in the United States. Pharmacy (Basel). 2019; 7(2). PMC: 6632048. DOI: 10.3390/pharmacy7020060. View

16.

Strand M, Eukel H, Frenzel O, Skoy E, Steig J, Werremeyer A . Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model. Res Social Adm Pharm. 2019; 16(9):1248-1254. DOI: 10.1016/j.sapharm.2019.11.016. View

17.

Xu J, Davis C, Cruz M, Lurie P . State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug Alcohol Depend. 2018; 189:37-41. DOI: 10.1016/j.drugalcdep.2018.04.020. View

18.

Irwin A, Novak K, Alley L, Havlin T, OKane N, Johnston K . Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge. J Am Pharm Assoc (2003). 2020; 60(3):450-455.e3. DOI: 10.1016/j.japh.2019.11.030. View

19.

Strand M, Eukel H . A Primary Prevention Approach to the Opioid Epidemic. Am J Public Health. 2019; 109(6):861-863. PMC: 6507985. DOI: 10.2105/AJPH.2019.305060. View

20.

Thomson K, Hillier-Brown F, Walton N, Bilaj M, Bambra C, Todd A . The effects of community pharmacy-delivered public health interventions on population health and health inequalities: A review of reviews. Prev Med. 2019; 124:98-109. DOI: 10.1016/j.ypmed.2019.04.003. View